DiGeorge Syndrome Drug Market to 2026: 2019 Global Analysis by Therapy Type, Treatment, Route of Administration, End-Users, Geography, Industry Growth, Competitive Landscape and Forecast Report

The Global DiGeorge Syndrome Drug Market report provides an in-depth overview of Product Specification, technology, product type and production analysis considering major factors such as Revenue, Cost, Gross and Gross Margin. The Global DiGeorge Syndrome Drug Market report also contains the drivers and restrains for the DiGeorge Syndrome Drug Market that are derived from SWOT analysis, and also shows what all the recent developments, product launches, joint ventures, merges and accusations by the several key players and brands that are driving the market are by systemic company profiles.

Get Free Sample Report | at https://databridgemarketresearch.com/request-a-sample/?dbmr=global-digeorge-syndrome-drug-market

Global DiGeorge Syndrome Drug Market By Therapy Type (Regenerative Medicine Advanced Therapy and Hormone Replacement Therapy), Treatment Type (Medication and Surgery), Route of Administration (Oral and Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends & Forecast to 2026

Key Market Players: Global DiGeorge Syndrome Drug Market

Few of the major competitors currently working in the global Digeorge syndrome drug market are Aevi Genomic Medicine, Inc, Bausch Health, Natera, Inc, Roche Sequencing, Enzyvant, Progenity, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Amgen Inc, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc, Angimmune LLC, Sumitomo Dainippon Pharma Co., Ltd., CELGENE CORPORATION, CELLECTAR BIOSCIENCES, INC, eFFECTOR Therapeutics, Inc., IMV Inc, Karyopharm, Neon Therapeutics, Novartis AG and many others.

Global DiGeorge syndrome drug market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. Growing incidence of DiGeorge syndrome’s population and development of newer therapies and treatment are the key factors for market growth

DiGeorge syndrome is also known as 22q11.2 deletion syndrome or velocardiofacial syndrome is a rare pediatric congenital condition where children are born with absence of chromosome 22. This results to severe immunodeficiency causing poor development of several body systems. Children with DiGeorge syndrome disorders have no ability to fight against infections.

According to the article puplished in Northwestern University, it is estimated that the incident population of DiGeorge Syndrome in the United States around 500 to 750 and over 2.5 million children diagnosed yearly. These growing incidents of DiGeorge syndrome’s population worldwide and robust pipeline for development of newer therapies are the key factors for market growth.

Market Drivers

• Vulnerable pediatric population of DiGeorge syndrome

• Emergence of drugs for treating serious disease such as CNS disorders and cardiovascular diseases associated with DiGeorge syndrome

• Increase in the rate of R&D initiatives is driving DiGeorge syndrome therapeutics market

Market Restraints

• Effective treatment is either unavailable or unaffordable

• Patent expiry from many companies and introduction of generic drugs of branded version is expected to restrain the growth if the market

• Inadequate knowledge about DiGeorge syndrome in some developing countries

Table of Content: Global DiGeorge Syndrome Drug Market

Part 01: Executive Summary

Part 02: Scope of The Report

Part 03: Global DiGeorge Syndrome Drug Market Landscape

Part 04: Global DiGeorge Syndrome Drug Market Sizing

Part 05: Global DiGeorge Syndrome Drug Market Segmentation By Product

Part 06: Five Forces Analysis

Part 07: Customer Landscape

Part 08: Geographic Landscape

Part 09: Decision Framework

Part 10: Drivers And Challenges

Part 11: Market Trends

Part 12: Vendor Landscape

Part 13: Vendor Analysis

And More…..Get Detailed TOC | at https://databridgemarketresearch.com/toc/?dbmr=global-digeorge-syndrome-drug-market

Segmentation: Global DiGeorge Syndrome Drug Market

By Therapy Type

• Regenerative Medicine Advanced Therapy
• Hormone Replacement Therapy

By Treatment

• Medication
o Vitamin D and Calcium
• Surgery
o Palatoplasty
o Heart defects
o Others

By Route of administration

• Oral
• Injectable

By End Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

By Geography

• North America

• South America

• Europe

• Asia-Pacific

• Middle East & Africa

Key Developments in the Market:

• In June 2019, Enzyvant’s drug candidate RVT-802, a tissue-based regenerative therapy received the FDA acceptance of Biologic License Application (BLA) as well as Priority Review status for the treatment of pediatric congenital athymia associated with complete DiGeorge Anomaly (cDGA), CHARGE syndrome, and FOXN1 deficiency. If approved, it will be the first drug used for the treatment of DiGeorge syndrome and turning it into a potential blockbuster commercial milestone for Enzyvant.

• In September 2017, Enzyvant received Rare Pediatric Disease designation from the FDA for RVT-802, a tissue-based regenerative therapy for treatment of congenital athymia associated with complete DiGeorge Syndrome. The FDA Rare Pediatric Disease designation will enable to receive a rare pediatric disease priority review voucher upon approval of Biologic License Application (BLA).

Competitive Analysis:

Global DiGeorge syndrome drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Digeorge syndrome drug market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Reasons to Purchase this Report

• Current and future of global Digeorge syndrome drug market outlook in the developed and emerging markets

• The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period

• Regions/Countries that are expected to witness the fastest growth rates during the forecast period

• The latest developments, market shares, and strategies that are employed by the major market players

Buy Full Report | at https://databridgemarketresearch.com/checkout/buy/enterprise/global-digeorge-syndrome-drug-market

Contact:

Data Bridge Market Research
Tel: +1-888-387-2818
Email: sopan.gedam@databridgemarketresearch.com

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

This release was published on openPR.